Brief: Asit Biotech announces last patient last visit in phase IIa clinical study with hdm-ASIT+ product

European Medical Solutions SA

24/01/2017 06:31

Jan 24 (Reuters) - Asit Biotech  ASIT.BR : 
    * Announces last patient last visit in the phase IIa clinical study with its hdm-ASIT+ 
    * Product candidate for treating house dust mite rhinitis 
    * 89 pct of patients who began treatment attended study's last visit 
    * No major adverse event has been observed 
    * Clinical data is currently being verified 
    * Results should be published before end of Q1 of 2017 
 
Source text for Eikon:  ID:nBw1SjvxVa  
Further company coverage:  ASIT.BR  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))